Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbott Laboratories (ABT) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 69,532,888
  • Shares Outstanding, K 1,470,000
  • Annual Sales, $ 20,405 M
  • Annual Income, $ 4,423 M
  • 36-Month Beta 0.92
  • Price/Sales 3.36
  • Price/Book 2.84

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.90 +6.75%
on 12/21/16
41.62 -2.79%
on 01/10/17
+2.27 (+5.94%)
since 12/20/16
3-Month
37.38 +8.24%
on 12/01/16
41.62 -2.79%
on 01/10/17
-0.28 (-0.69%)
since 10/20/16
52-Week
36.00 +12.39%
on 01/28/16
45.79 -11.64%
on 08/02/16
+0.50 (+1.25%)
since 01/20/16

Most Recent Stories

More News
New Study Demonstrates Spinal Cord Stimulation Can Reduce or Stabilize Opioid Use Among Chronic Pain Patients

New research has found spinal cord stimulation (SCS) therapy can be key to reducing or stabilizing the use of opioids in patients battling chronic pain. In a new study, researchers examined opioid usage...

What's in Store for Abbott Labs (ABT) This Earnings Season?

Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.

OilPrice.com: This Could Be the Biggest Winner of 2017's Biotech Boom

OilPrice.com Market Commentary: The catalysts for a major biotech rally in 2017 are already multiplying-not least because of the Trump presidential victory-and one little-known company is poised for huge...

Global Nucleic Acid Testing Market 2016-2020: Advances in Precision & Personalized Medicine with Abbott Laboratories, Roche Molecular Systems, Siemens Healthineers, Hologic & Qiagen Dominating - Research and Markets

Research and Markets has announced the addition of the "Global Nucleic Acid Testing Market 2016-2020" report to their offering.

OilPrice.com: Life-Saving Device Could Transform the Medical Market in 2017

OilPrice.com Market Commentary: A little-known biotech company is poised to potentially earn millions in revenue with the planned upcoming release of a breakthrough technology that could prevent massive...

Asian stocks mixed after China data

SEOUL, South Korea (AP) — Asian stock markets were mixed on Friday as disappointing Chinese trade data dented already bleak investor sentiment following U.S. President-elect's Donald Trump's news conference....

Analyst Reports for Facebook, Bank of America & ConocoPhillips

Analyst Reports for Facebook, Bank of America & ConocoPhillips

US warns of unusual cybersecurity flaw in heart devices

WASHINGTON (AP) — The Homeland Security Department warned Tuesday about an unusual cybersecurity flaw for one manufacturer's implantable heart devices that it said could allow hackers to remotely take...

Blog Coverage ReWalk Announced 2017 Outlook; to Reduce Operating Expenses by up to 30%

Upcoming AWS Coverage on Abbott Laboratories

Abbott Completes the Acquisition of St. Jude Medical

Abbott announced today it has completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena. The transaction provides Abbott with expanded opportunities...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

See More

Support & Resistance

2nd Resistance Point 40.95
1st Resistance Point 40.70
Last Price 40.42
1st Support Level 40.28
2nd Support Level 40.11

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.